The relationship between circulating irisin, retinol binding protein-4, adiponectin and inflammatory mediators in patients with metabolic syndrome. 2017

Omur Tabak, and Gonul Simsek, and Fusun Erdenen, and Volkan Sozer, and Tuna Hasoglu, and Remise Gelisgen, and Esma Altunoglu, and Cuneyt Muderrisoglu, and Abdulhalim Senyigit, and Hafize Uzun
Internal Medicine Clinic, lstanbul Kanuni Sultan Suleyman Education and Research Hospital, Istanbul, Turkey.

OBJECTIVE We wanted to investigate whether there is a relationship between circulating irisin, retinol binding protein-4 (RBP-4), adiponectin and proinflammatory mediators implicated in the development of insulin resistance (IR) in metabolic syndrome (MetS). METHODS In 180 individuals, including controls and patients with MetS, we measured fasting plasma insulin, high sensitivity C-reactive protein (hsCRP), pentraxin-3 (PTX-3), interleukin-33 (IL-33), irisin, RBP-4, and adiponectin using ELISA kits. RESULTS While fasting plasma hsCRP, PTX-3, IL-33, irisin, RBP-4 concentrations were higher, adiponectin levels were lower in patients with MetS than in controls. A correlation analysis revealed that plasma irisin levels were positively associated with MetS components such as waist circumference and waist-hip ratio, low density lipoprotein (LDL) and markers of systemic inflammation such as PTX-3, hsCRP, uric acid, and RBP-4. Adiponectin levels were negatively associated with waist circumference, waist-hip ratio, PTX-3 and LDL. CONCLUSIONS Although the precise mechanisms are still unclear, irisin, RBP-4, adiponectin and PTX-3 are hallmarks of the MetS, which is related to low-grade inflammation. It is conceivable that irisin and adiponectin might contribute to the development of MetS and may also represent novel MetS components. Future clinical studies are needed to confirm and extend these data.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D005353 Fibronectins Glycoproteins found on the surfaces of cells, particularly in fibrillar structures. The proteins are lost or reduced when these cells undergo viral or chemical transformation. They are highly susceptible to proteolysis and are substrates for activated blood coagulation factor VIII. The forms present in plasma are called cold-insoluble globulins. Cold-Insoluble Globulins,LETS Proteins,Fibronectin,Opsonic Glycoprotein,Opsonic alpha(2)SB Glycoprotein,alpha 2-Surface Binding Glycoprotein,Cold Insoluble Globulins,Globulins, Cold-Insoluble,Glycoprotein, Opsonic,Proteins, LETS,alpha 2 Surface Binding Glycoprotein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

Omur Tabak, and Gonul Simsek, and Fusun Erdenen, and Volkan Sozer, and Tuna Hasoglu, and Remise Gelisgen, and Esma Altunoglu, and Cuneyt Muderrisoglu, and Abdulhalim Senyigit, and Hafize Uzun
April 2011, Korean circulation journal,
Omur Tabak, and Gonul Simsek, and Fusun Erdenen, and Volkan Sozer, and Tuna Hasoglu, and Remise Gelisgen, and Esma Altunoglu, and Cuneyt Muderrisoglu, and Abdulhalim Senyigit, and Hafize Uzun
November 2011, Wiener medizinische Wochenschrift (1946),
Omur Tabak, and Gonul Simsek, and Fusun Erdenen, and Volkan Sozer, and Tuna Hasoglu, and Remise Gelisgen, and Esma Altunoglu, and Cuneyt Muderrisoglu, and Abdulhalim Senyigit, and Hafize Uzun
July 2009, Diabetes research and clinical practice,
Omur Tabak, and Gonul Simsek, and Fusun Erdenen, and Volkan Sozer, and Tuna Hasoglu, and Remise Gelisgen, and Esma Altunoglu, and Cuneyt Muderrisoglu, and Abdulhalim Senyigit, and Hafize Uzun
January 2012, Experimental dermatology,
Omur Tabak, and Gonul Simsek, and Fusun Erdenen, and Volkan Sozer, and Tuna Hasoglu, and Remise Gelisgen, and Esma Altunoglu, and Cuneyt Muderrisoglu, and Abdulhalim Senyigit, and Hafize Uzun
May 2014, Metabolic syndrome and related disorders,
Omur Tabak, and Gonul Simsek, and Fusun Erdenen, and Volkan Sozer, and Tuna Hasoglu, and Remise Gelisgen, and Esma Altunoglu, and Cuneyt Muderrisoglu, and Abdulhalim Senyigit, and Hafize Uzun
December 2011, Progress in neuro-psychopharmacology & biological psychiatry,
Omur Tabak, and Gonul Simsek, and Fusun Erdenen, and Volkan Sozer, and Tuna Hasoglu, and Remise Gelisgen, and Esma Altunoglu, and Cuneyt Muderrisoglu, and Abdulhalim Senyigit, and Hafize Uzun
September 2023, Biomolecules,
Omur Tabak, and Gonul Simsek, and Fusun Erdenen, and Volkan Sozer, and Tuna Hasoglu, and Remise Gelisgen, and Esma Altunoglu, and Cuneyt Muderrisoglu, and Abdulhalim Senyigit, and Hafize Uzun
January 2019, Hormone molecular biology and clinical investigation,
Omur Tabak, and Gonul Simsek, and Fusun Erdenen, and Volkan Sozer, and Tuna Hasoglu, and Remise Gelisgen, and Esma Altunoglu, and Cuneyt Muderrisoglu, and Abdulhalim Senyigit, and Hafize Uzun
November 2025, Biomolecules & biomedicine,
Omur Tabak, and Gonul Simsek, and Fusun Erdenen, and Volkan Sozer, and Tuna Hasoglu, and Remise Gelisgen, and Esma Altunoglu, and Cuneyt Muderrisoglu, and Abdulhalim Senyigit, and Hafize Uzun
September 2019, The Journal of dermatology,
Copied contents to your clipboard!